SCHIELD Implant

Product Overview

Alternative Name: SCHIELD Biodegradable MPT Implant

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Subdermal

Duration Type: Long-acting

Description: The SCHIELD implant will be designed for sustained, long-acting delivery of API, capable of dual indication (anti-retroviral plus contraceptive) with zero-order release kinetics. This biodegradable, reversible implant will be subcutaneously placed, discrete, and user-independent to eliminate patient burden.

Updated date: May 30, 2018

Vertical Tabs

Product Details

Inactive material: Polycaprolactone; GRAS excipient

Potential Multi-Purpose Technology (MPT): Yes

Regimen: single subcutaneous injection every 12 months

Duration: 12-18 months

Partner: RTI International

Status

Project Phase: Early Development

Project Stage: Pre-clinical

Began discovery in: July 2017

Status Details:
This product is still in the early development phase. The API screening and formulations are currently underway, as well as implant fabrication and prototyping.

Programmatic Considerations

Considerations:
Both sociobehavioral research and market adoption studies in collaboration with our partners in sub-Saharan African regions will take place under the SCHIELD program. Results from end user studies working with relevant populations and health care practitioners will influence the early stages of product development to optimize future uptake of this MPT product.

Additional Information

Additional Information:
Press Release: https://www.rti.org/news/new-multipurpose-device-help-prevent-hiv-and-pregnanc

Footnotes:
SCHIELD stands for Subcutaneous Contraceptive and HIV Implant Engineered for Long-acting Development. Builds on earlier Capronor implant work, see Capronor entry.

Download Product Report

Alternative Name: SCHIELD Biodegradable MPT Implant

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Subdermal

Duration Type: Long-acting

Updated date: May 30, 2018

Vertical Tabs

Inactive material: Polycaprolactone; GRAS excipient

Potential Multi-Purpose Technology (MPT): Yes

Regimen: single subcutaneous injection every 12 months

Duration: 12-18 months

Partner: RTI International

Project Phase: Early Development

Project Stage: Pre-clinical

Began discovery in: July 2017

Status Details: This product is still in the early development phase. The API screening and formulations are currently underway, as well as implant fabrication and prototyping.

Additional Information: Press Release: https://www.rti.org/news/new-multipurpose-device-help-prevent-hiv-and-pregnanc

Footnotes: SCHIELD stands for Subcutaneous Contraceptive and HIV Implant Engineered for Long-acting Development. Builds on earlier Capronor implant work, see Capronor entry.

Status Details:
This product is still in the early development phase. The API screening and formulations are currently underway, as well as implant fabrication and prototyping.

Additional Information:
Press Release: https://www.rti.org/news/new-multipurpose-device-help-prevent-hiv-and-pregnanc

Footnotes:
SCHIELD stands for Subcutaneous Contraceptive and HIV Implant Engineered for Long-acting Development. Builds on earlier Capronor implant work, see Capronor entry.